U.S. FDA approves Akebia’s anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics’ drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday.
The U.S. Food and Drug Administration approved Akebia Therapeutics’ drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday.
MD, DO. OD, PA, NP, PhD, PsyD, CRNA. OK—confused yet? Explore what distinguishes physicians from other members of the health care team.
Cancer diagnoses are on the rise among younger adults, and a new guidebook seeks to arm employers with the tools necessary to tackle this issue.…
Super Bowl parade victims, a new covid variant, abortion, gender care, cancer deaths among Black women, cyberattacks, and more.
13 -15 MAY 2024 | Abu Dhabi, UAE Be part of a global platform providing an interdisciplinary view of the health innovation landscape and future…
California Gov. Gavin Newsom and state lawmakers are announcing legislation Wednesday aimed at helping Arizonans access abortions after the Arizona Supreme Court allowed a near…
A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene.
View Full-Length Video at: https://youtu.be/Rw_VeyFyGZIRelated Article Available at: https://mayocl.in/3Vj6PzS
Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage…
Employers are in a strong position to lead the charge in changing the conversation around obesity care, according to a new report from the Milken…
A Manager’s Guide to Unlocking High Performance in Employees with ADHD, Autism, Dyslexia, and Other Neurodivergencies